Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

MONALEESA-3 Update Confirms Ribociclib OS Advantage

A final analysis has verified that ribociclib plus fulvestrant improves hormone receptor-positive, HER2-negative advanced breast cancer survival
16 Dec 2019
Anticancer Agents;  Breast Cancer

Author: By Lynda Williams, Senior medwireNews Reporter 

 

medwireNews: The second interim analysis of the MONALEESA-3 trial has demonstrated a significant overall survival (OS) improvement for women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer with the use of ribociclib and fulvestrant versus fulvestrant alone. 

At 42 months, 57.8% of the 484 patients randomly assigned to receive ribociclib plus fulvestrant were alive versus 45.9% of the 242 patients who instead received placebo plus fulvestrant, giving a significant hazard ratio (HR) for death of 0.72 in favour of the CDK4/6 inhibitor. 

Median OS in the phase III trial was not reached with ribociclib plus fulvestrant versus 40.0 months with placebo plus fulvestrant.  

As the OS results crossed the prespecified efficacy criteria for stopping, this will be the final analysis of the trial protocol, reported Dennis Slamon, from the UCLA Translational Oncology Research Lab in Santa Monica, California, USA, at the San Antonio Breast Cancer Symposium in Texas, USA. 

The study findings – also reported in The New England Journal of Medicine – demonstrated that the OS “benefit was consistent across most subgroups” although the confidence intervals were wide for some subgroups with small patient numbers. This included a significant benefit with ribociclib use regardless of whether patients received the trial regimen first-line (HR=0.70) or had an early relapse or received the regimen as a second-line (HR=0.73) therapy. 

The investigators also reported a descriptive update for progression-free survival for the first-line therapy subgroup, with a median duration of 33.6 months with ribociclib plus fulvestrant versus 19.2 months for placebo and fulvestrant. 

“This finding, together with data on overall survival, may support consideration of ribociclib plus fulvestrant as initial therapy in patients with advanced disease”, they write, noting that the results also support its use among patients with early relapse and as a second-line therapy.

The team concludes: “The combinations of ribociclib with fulvestrant in the MONALEESA-3 trial and with endocrine therapy, particularly nonsteroidal aromatase inhibitors, in the MONALEESA-7 trial have shown a consistent and meaningful prolongation of survival over placebo.

“Indeed, both trials showed an approximate 30% difference in the relative risk of death with ribociclib as compared with placebo in combination with different endocrine-therapy partners, regardless of menopausal status in patients with hormone receptor–positive, HER2-negative advanced breast cancer.” 

 

Reference 

Slamon DJ, Neven P, Chia S, et alOverall survival with ribociclib plus fulvestrant in advanced breast cancerEngl J Med; Advance online publication 11 December 2019. DOI: 10.1056/NEJMoa1911149 

medwireNews (www.medwireNews.com ) is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.